妊娠期登革热疫苗接种——临床试验数据概览
基于19项CYD-TDV临床试验数据,描述妊娠期意外接种登革热疫苗后的妊娠结局。CYD-TDV组暴露妊娠58例中47例(81%)健康活产、6例(10.3%)妊娠丢失;安慰剂组暴露妊娠30例中25例(83%)健康活产、4例(13.3%)妊娠丢失。在小数据集内,与对照组相比未发现早期妊娠意外接种CYD-TDV后不良妊娠结局增加的证据。
要点
- CYD-TDV为减毒四价登革热疫苗,已在多个流行国家获批,妊娠期禁用。
- CYD-TDV组暴露妊娠58例中81%健康活产、10.3%妊娠丢失;安慰剂组暴露妊娠30例中83%健康活产、13.3%妊娠丢失。
- 所评估的小数据集内,未发现早期妊娠意外接种CYD-TDV后不良妊娠结局较对照组增加的证据。
核心结论
- 在所评估的小数据集内,与对照组相比,未发现早期妊娠意外接种CYD-TDV后不良妊娠结局增加的证据。
研究设计与样本
- 数据来自作为CYD-TDV临床开发一部分所开展的19项临床试验。
- 在预先设定的妊娠风险窗口(末次月经日期前30天至妊娠结束)内接种CYD-TDV或安慰剂的女性视为暴露,试验期间非风险期发生的妊娠视为非暴露。
- 共报告615例妊娠:CYD-TDV组404例,安慰剂组211例;7例妊娠(CYD-TDV组5例、安慰剂组2例)暴露情况无法确定。
- 妊娠丢失定义为流产(自然流产或未指明类型)、宫内死亡和死产。
主要发现
- CYD-TDV组58例妊娠视为暴露,其中47例(81%)健康活产,6例(10.3%)妊娠丢失,3例选择性终止妊娠,2例结局未知。
- 安慰剂组30例妊娠视为暴露,其中25例(83%)健康活产,4例(13.3%)妊娠丢失,1例选择性终止妊娠。
- 非暴露妊娠中多数为健康活产;CYD-TDV组23/341(6.7%)和安慰剂组17/179(9.5%)发生妊娠丢失。
- 大多数报告的妊娠丢失发生在不良妊娠结局高危女性中,主要归因于年轻年龄。
临床怎么用
- CYD-TDV在多个流行国家获批,妊娠期禁用。
- 原文未据此给出推荐。
局限性
- 所评估的数据集较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The live, attenuated, tetravalent dengue vaccine (CYD-TDV) is licensed in several endemic countries and contraindicated during pregnancy. Inadvertent vaccination during pregnancy may occur during clinical trials that include women of childbearing age. The potential risk associated with dengue vaccination in pregnancy remains unknown. We describe pregnancy outcomes following inadvertent dengue vaccination in pregnancy from CYD-TDV trial data. METHODS: Data were collected from trials conducted as part of the CYD-TDV clinical development. Women who received CYD-TDV or placebo during the pre-specified pregnancy risk window (from 30 days before the date of their last menstrual period to end of pregnancy) were considered as exposed; pregnancies occurring in non-risk periods during the trials were considered to be non-exposed. Pregnancy losses were defined as abortion (spontaneous or unspecified), death in utero, and stillbirth. RESULTS: 615 pregnancies were reported from 19 CYD-TDV trials: 404 in the CYD-TDV arm, and 211 in the placebo arm. Exposure could not be determined for 7 pregnancies (5, CYD-TDV; 2, placebo). In the CYD-TDV arm, 58 pregnancies were considered as exposed. Most of these (n = 47, 81%) had healthy live births; 6 (10.3%) had pregnancy losses; 3 underwent elective termination and 2 had unknown outcome. In the placebo group, 30 pregnancies were considered exposed. Most of these (n = 25, 83%) had healthy births; 4 (13.3%) had pregnancy losses; and 1 had elective termination. Among non-exposed pregnancies, most resulted in healthy live births; 23/341 (6.7%) in the CYD-TDV group and 17/179 (9.5%) in the placebo group had pregnancy losses. Most reported pregnancy losses were in women considered high-risk for adverse pregnancy outcome, primarily due to young age. CONCLUSION: In the small dataset assessed, no evidence of increased adverse pregnancy outcomes has been identified from inadvertent immunization of women in early pregnancy with CYD-TDV compared with the control group.
引用
- Skipetrova A, Wartel TA, Gailhardou S, et al. Dengue vaccination during pregnancy - An overview of clinical trials data. Vaccine. 2018. PMID: 29716774. doi:10.1016/j.vaccine.2018.04.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。